Mark A. Socinski, MD, AdventHealth Cancer Institute
Advertisement
Articles by Mark A. Socinski, MD, AdventHealth Cancer Institute
Advertisement
Latest Updated Articles
Impact of Payers on the Costs of DrugsPublished: August 16th 2021 | Updated:
Personalized Therapies Based on Innovation and AffordabilityPublished: August 16th 2021 | Updated:
Appropriateness for Durvalumab in Unresectable Stage III NSCLCPublished: August 4th 2021 | Updated:
Neoadjuvant Immunotherapy for Resectable NSCLCPublished: August 11th 2021 | Updated:
Frontline Treatment of PD-L1+ Stage IV NSCLC: CemiplimabPublished: June 30th 2021 | Updated:
Durvalumab for Unresectable Stage III NSCLCPublished: July 28th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5